Onglyza, a diabetes drug from Bristol-Myers Squibb and AstraZeneca, does not appear to raise the risk of heart attacks and other heart problems, the FDA said after reviewing tests submitted by the companies. An FDA panel is set to meet Wednesday to evaluate the drug's use in patients with Type 2 diabetes.

Full Story:

Related Summaries